Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price dropped 22.9% on Friday . The company traded as low as C$0.18 and last traded at C$0.19. Approximately 504,239 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The firm has a market capitalization of C$26.96 million, a PE ratio of -5.39 and a beta of 0.20. The firm’s 50 day moving average price is C$0.19 and its 200-day moving average price is C$0.11.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Stock Analyst Ratings and Canadian Analyst Ratings
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
- Learn Technical Analysis Skills to Master the Stock Market
- Forget Tesla: 3 Stocks to Ride the Elon Musk Effect
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- David Tepper Loads Up on China—These 5 Stocks Stand Out
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
